Sequins has released the WGS Clinical Control Set v1.0, designed around the ACMG Secondary Findings guidelines. Covering 80 genes and 96 conditions, this control set enables laboratories to benchmark detection and reporting of clinically actionable variants across cancer, cardiovascular, metabolic, and rare disease genes.
Developed to complement the WGS Core Control Set, this new product delivers in-sample validation of secondary findings, supporting accuracy, reproducibility, and regulatory readiness in clinical sequencing.
